Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938449 | 0.86 | CYP4A11 (0.53) | ESR1ESR2PTPRBPPARAMIF | |
| SCHEMBL163965 | 0.86 | NOS2 (0.47) | ESR1ESR2PPARGPPARAALDH1A1 | |
| SCHEMBL4816689 | 0.86 | ESR1 (0.63) | ESR1ESR2MIF | |
| SCHEMBL3248350 | 0.86 | L3MBTL1 (0.49) | ESR1ESR2PTPRBPPARGPPARA | |
| SCHEMBL5672844 | 0.84 | LDHA (0.59) | PPARGPPARAALDH1A1LDHA | |
| SCHEMBL3204956 | 0.84 | ATM (0.53) | MIFALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL9570612 | 0.83 | ESR1 (0.44) | ESR1ESR2PTPRBPPARGPPARA | |
| Ammonia Solution, Strong SCHEMBL20513680 | 0.82 | ATM (0.51) | MIFALDH1A1THRBCYP2C9CYP2C19 | |
| Methylene Chloride SCHEMBL29038775 | 0.81 | ATM (0.50) | MIFALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL12142729 | 0.80 | ALDH1A1 (0.48) | ESR1ESR2PTPRBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | disclosed |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-8785681-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2014-07-22 | — | — | US | disclosed |
| EP-2125711-B1 | 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2125711-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Albireo Ab (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008108735-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | TPMT, FABP2, PTGES2 | ESR1 3074/4885ESR2 648/4885PTPRB 482/4885 |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | ESR1 3384/4885ESR2 576/4885PTPRB 502/4885 |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | ESR1 3384/4885ESR2 576/4885PTPRB 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.